Physician profile
Candice Case
NPI 1649042987
$2,205.65
in general payments reported to CMS, 2019-2025
18 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $911 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $602.53 | 2024-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $549.65 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Verona Pharma, INC. | $182.15 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $152.40 | 2024-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $107.54 | 2024-2025 | |
| Axsome Therapeutics, INC. | $80.88 | 2025 | Sunosi |
| Harmony Biosciences LLC | $80.81 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.50 | 2024-2025 | Glassia |
| Electromed, INC. | $76.35 | 2024-2025 | Smartvest |
| Lilly USA, LLC | $54.29 | 2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $50.18 | 2024-2025 | Dupixent |
| Viatris Specialty LLC | $49.58 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $40.31 | 2024-2025 | Lumryz |
| Paratek Pharmaceuticals, INC. | $26.47 | 2025 | Nuzyra |
| Mallinckrodt Hospital Products INC. | $22.77 | 2024 | Acthar |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.61 | 2024 | Tezspire |
| Mylan Specialty L.P. | $17.93 | 2024 | Yupelri |
| Vifor Pharma, INC. | $14.70 | 2025 | Zemaira |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.